ad best idea list
wedbush equiti research depart focus deliv alpha within consum fig
healthcar tmt vertic best idea list compris highest rate equiti chosen
analyst vet invest committe manag risk avoid thesi creep employ
automat sale rule stock move rel basi versu averag move
 russel
past perform indic futur result actual perform may differ
perform inform contain herein price perform inform base data
statist servic report sourc ws believ reliabl accuraci
guarante result present report neither reflect inclus dividend deduct
commiss cost fee expens commiss cost fee expens reduc
actual return volatil and/or benchmark index present materi
differ model portfolio use illustr gener market condit
result portray benchmark indic unmanag invest directli
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
revenu growth tie share gain pc server cpu rather broader
market trend lower market growth weigh revenue/earn continu
share shift gain roughli allow outperform market
peer struggl econom trend
new game consol minim revenu current provid substanti revenu
boost
vast bulk revenu tie game data center pc three
segment anticip outperform downturn particularli peopl shift
toward remot work consumpt entertain involv person
current environ clearli creat signific uncertainti
intermedi term guid look conserv prior concern around
appear setup insul contrast peer
strong balanc sheet net cash moreov shed
fab asset either fab util risk exposur signific capit
requir weigh semiconductor firm difficult environ
profit anticip fda approv
valrox/hemophilia gene therapi cure august adcomm -- latest note march
bmn pdufa recal februari compani announc bla accept
valoctocogen roxaparvovec valrox treatment sever hemophilia grant prioriti
review fda assign pdufa target action date august notifi
current plan hold advisori committe meet manag
anticip need adcomm base correspond fda bla
packag includ updat phase data interim analysi on-going phase
studi interim phase result demonstr substanti reduct annual bleed rate
abr fviii usag post-valrox infus vs baselin pleas refer may research
note addit detail base valrox clinic dataset anticip approv
project annual sale could reach estim launch eu
launch row launch start project cash runway profit
current share price heavili discount multipl near-term opportun
launch ayvakit pdgfra gist like gain approv late line gist may report
posit data line gist see littl risk start registr part
studi avapritinib indol system mastocytosi ism
expect posit data voyag studi avapritinib line gist
near-term catalyst increas confid ayvakit posit gist market
smooth transit part pioneer ism investor
rightli concern clinic trial postpon note follow point
favor studi site investig larg alreadi board
recent conclud part studi schedul initi patient screen
around end june could end control measur pandem
 primari endpoint measur symptom score done home patient
via electron devic
pralsetinib nda ret mutat lung cancer complet march
approv expect give anoth market drug one
feel under-valued investor overli concern competit
posit like quarter behind loxo/lli launch view
drug essenti equival split market
compani cash get compani near-
term covid market weak well ayvakit launch allow
financi flexibl revenu cheaper debt becom financ option royalti
advantag vs mani peer deal given better end
market exposur rev game datacent fabless model
 limit capital-expenditure depreci strong balanc sheet
leadership core market attract longer term growth prospect
believ game ai enjoy long term growth respect
see forthcom releas amper expect acquisit mlnx
attract valuat trade estim year
number think possibl mlnx ad result price target
suggest upsid current level
ad wedbush bil expect compar less sale declin
peer advers impact system compstore growth rang per
recent check lower wing cost provid potenti tailwind tune bp per
declin current yoy believ pois somewhat off-set labor
opex de-lever littl liquidity/credit risk low risk scenario
would need subsid franchise materi lower pt
reiter outperform rate
wedbush research certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view
contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
march
march
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
ws make market secur
ws co-manag public offer secur within last month
ws receiv compens invest bank servic within last month
ws provid invest bank servic within last month
rate histori
power bluematrix
power bluematrix
rate histori
power bluematrix
rate histori
rate histori
power bluematrix
power bluematrix
wingstop inc rate histori
wedbush disclosur price chart updat within first fifteen day new calendar quarter per finra regul price
